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Abstract
Background: Up to 75% of patients with Crohn's disease (CD) will have intestinal resection during
their life. Most patients will, however, develop postoperative recurrence (endoscopic, clinical
or surgical). Several medical and surgical strategies have been attempted to prevent postoper-
ative recurrence. This review evaluates the efficacy of different drug regimens and surgical
techniques in the prevention of clinical, endoscopic and surgical postoperative recurrence of
CD.
Methods: A literature search for randomized controlled trials on medical or surgical interven-
tions was performed. The endpoints for efficacy were clinical, endoscopic and surgical recur-
rence. Meta-analyses were performed in case two or more RCTs evaluated the same drug or
surgical technique.
Results: Mesalamine is more effective in preventing clinical recurrence than placebo
(P=0,012), as well as nitroimidazolic antibiotics at one year follow-up (Pb0.001) and thiopurines
(P=0.018). Nitroimidazolic antibiotics are also more effective than placebo in preventing
endoscopic recurrence (P=0.037), as well as thiopurines (P=0.015) and infliximab (P=0.006).
Budenoside, probiotics, Interleukin-10 nor any of the different surgical procedures showed any
significant difference compared to placebo in postoperative recurrence rates of CD.
Conclusion: Among the different drug regimens and surgical techniques, only thiopurines and
nitroimidazolic antibiotics are able to reduce postoperative clinical as well as endoscopic; CDAI, Crohn's disease Activity Index; CI, Confidence Interval; IL-10, Interleukin-10; E–E, End-to-end;
oE, Level of Evidence; GoR, Grade of Recommendation.
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638 E.S. van Loo et al.recurrence of CD. Mesalamine and infliximab also seem to be superior to placebo in preventing
clinical recurrence and endoscopic recurrence, respectively. There is a paucity of trials evaluat-
ing long-term follow-up and prevention of surgical recurrence of CD.
© 2011 Published by Elsevier B.V. on behalf of European Crohn's and Colitis Organisation.Contents
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Crohn's disease (CD) is a chronic inflammatory bowel disease
(IBD) that can affect any part of the gastrointestinal tract.
Most commonly it involves the terminal ileum and proximal
colon. Genetic and environmental factors play a role in its eti-
ology and pathogenesis.1–3 The most common age at time of
diagnosis is usually during late adolescence and early adult-
hood, although CD can appear at almost any age. Most patients
are diagnosed before the age of 40 years.4,5 Overall, the inci-
dence of CD is approximately 5–10 per 100.000 per year with a
prevalence of 50–100 per 100.000.1,2,4
The clinical course of CD is characterized by exacerbations
and remissions. Eventually, recurrent inflammation can cause
bowel strictures, fistulae (often perianal) or abscesses. Extra-
intestinal manifestations most commonly involve the skin,
eyes, joints and biliary tract.2,4,5
Medical management of CD is a rapidly evolving field, with
many new biologicals under investigation. There are multiple
medical treatments that proved to be effective in inducing
clinical response and remission. The appropriate choice for
medication not only depends on the activity, location and be-
havior of the disease, but is also influenced by the balance be-
tween drug potency and side effects; previous response to
treatment and the presence of extraintestinal manifestations,
or complications.4,6 Operative management can be effectivein managing disease complications and improving quality of
life.7 Eventually, around 75–80% of the patients will end up
with a surgical resection.6,8–15 Surgery, however, does not
eliminate the pathogenic process, as most patients develop
recurrence of disease.8,11,13,16–18 Although a wide range of
postoperative recurrence rates has been reported according
to the definitions of recurrence (clinical, endoscopic or surgi-
cal recurrence), there is common agreement that recurrence
rate steadily increases with time, reaching approximately
50% at 20 years after surgery.18 Clinical postoperative recur-
rence rates have been recorded between 17–55% at 5 years,
32%–76% at 10 years and 72% at 20 years, whereas postopera-
tive surgical recurrence rates are 11%–32% at 5 years, 20%–
44% at 10 years and 46%–55% at 20 years.14
Several studies have reported about prognostic factors for
postoperative recurrence of CD. To date, only smoking is con-
vincingly associated with a higher risk of recurrence.12–15,19,20
The identification of such risk factors is very important to se-
lect patients who may benefit from pro-active preventive
measures.
Several medical and surgical strategies have been
attempted to prevent postoperative recurrence. Most studies,
however, only evaluate clinical and/or endoscopic recur-
rence. Little is known about the incidence of surgical recur-
rence. Therefore, this review focuses on the efficacy of
different medication regimes and surgical procedures in the
639Prevention of postoperative recurrence of Crohn's diseaseprevention of clinical, endoscopic and surgical postoperative
recurrence of CD.
2. Methods
2.1. Literature search
Randomized controlled clinical trials for prevention of post-
operative recurrence of Crohn's disease were identified from
the Medline electronic database and Embase from 1966 until
July 2010. The following search terms were used: Crohn
(Crohn's disease), recurrence and surgery or postoperative.
The studies were limited to randomized controlled trials,
humans and English language. Cross-referencing was used
to identify additional articles. This resulted in 105 studies.
Studies were included for analysis if they met all of the fol-
lowing inclusion criteria: 1) the study was a controlled
study, 2) all study patients had a surgical induced remission
of their CD, 3) the study reported the definition of recur-
rence, and 4) data on clinical and/or endoscopic and/or sur-
gical recurrence rates were available. This resulted in 44
studies. Eleven studies were excluded based on title and ab-
stract reading. Of five articles no full-text was available.
This resulted in 28 studies available for further assessment.
One study had postoperative recurrence as secondary end-
point, but the number of patients was too small to draw con-
clusions and was therefore excluded. One study only
described the placebo group of a previously published ran-
domized controlled trial which was already included. OnePotentially  relevant RCT's identified 
and screened for retrieval (n=44)
RCT's exclude
RCT's retrieved for more detailed 
evaluation (n=33)
Potentially appropriate RCT's to be 
included in the meta-analyses (n=28)
RCT's included in meta-analyses 
(n=25)
RCT's exclude
RCT's exclude
conclusions we
of patients (n=
RCT's withdra
elaborate in mo
Figure 1 Flowchart of studiesstudy was excluded because a more recent study analyzed
the same population with longer follow-up and was already
included. Eventually, 25 studies were included for analysis,
Fig. 1.
2.2. Outcome measures
The efficacy endpoints are in terms of recurrence rates. Clini-
cal recurrence was defined as symptoms associated with CD re-
quiring therapy and/or a CD activity index (CDAI) of at least 150
points and/or a rise in CDAI of 60–100 points. Endoscopic recur-
rence was defined according to the criteria of Rutgeerts.21 The
definition of surgical recurrence was the presence of clinical or
endoscopic recurrence refractory to medical treatment or
complications and requiring another surgical procedure.
2.3. Statistical methods
The method of analysis of the efficacy of a treatment was de-
pendent on the details provided in the paper describing the
study. If a clear description of withdrawn patients and their
state of recurrence at time of withdrawal was provided, the
evaluation of efficacy of the treatment was performed by a
per-protocol analysis. If no reasons for withdrawal or descrip-
tion of recurrences were given, an intention-to-treat method,
using the worst-case-model, was used. In this model, all pa-
tients who received at least one dose of a study drug were in-
cluded, and patients who were not assessed with respect to
the end point of the study were considered as failures. If thed based on title and abstract reading (n=11) 
d without full-text available (n=5)
d from meta-analysis because no 
re described because of too small numbers 
1) 
wn, because data were described more 
re recent studies(n=2)
included in meta-analyses.
640 E.S. van Loo et al.recurrence rate was reported as a percentage only, the num-
ber of patients with recurrence was extrapolated from the
total number of patients.
A meta-analysis was performed for each efficacy endpoint
if at least two studies evaluating the same drug or surgical pro-
cedure could be combined. Because of the differences in the
methods and the follow up length, we tested for statistical
heterogeneity. In case of statistical heterogeneity we used a
random effect model; in case of no statistical heterogeneity
a fixed effect model was used.22 To obtain an overall measure
of the efficacy of treatment, the overall risk difference be-
tween the frequencies of the events in both interventional
and control groups, as well as the 95% confidence intervals
(CI), were calculated. Results are shown in Forrest plots
when more than one study was found, with relative weights
added according to sample sizes.3. Results
3.1. Methodological quality of included studies
Of the 25 studies included in the meta-analysis 15 were
judged to had adequately concealed allocation. Of the
remaining 10 studies concealment of allocation was unclear
or inadequate.
In Table 1 an overview of all included studies with risk of
bias according to Cochrane's method is shown.23
In Table 2 a summary of all medical and surgical interven-
tions to prevent postoperative recurrence of CD is presented.Table 1 Risk of bias summary.
Adequate sequence
generation
Allocation
concealment
Regueiro 2009 Yes Yes
Caprilli 1994 Unclear Yes
Brignola 1995 Yes Yes
Florent 1996 Yes Yes
Lochs 2000 Yes Yes
Hanauer 2004 Yes Yes
McLeod 1995 Yes Yes
Caprilli 2003 Yes Yes
Rutgeerts 1995 Unclear Unclear
Rutgeerts 2005 Unclear Unclear
Ardizzone 2004 Yes No
D'Haens 2008 Yes Yes
Reinisch 2010 Yes Yes
Ewe 1999 Yes Yes
Hellers 1999 Unclear Unclear
Chermesh 2007 Unclear Unclear
Prantera 2002 Yes Unclear
Marteau 2006 Yes Yes
Van Gossum 2007 Yes Yes
Colombel 2001 Unclear Unclear
Fazio 1996 Yes Unclear
Cameron 1992 Yes Unclear
Ikeuchi 2000 Unclear Yes
McLeod 2009 Yes Yes
Stocchi 2008 Yes Unclear3.2. Drugs
3.2.1. Mesalamine
This drug has been extensively evaluated in the preven-
tion of postoperative recurrence of CD.
Seven controlled trials have evaluated the role of mesala-
mine on the effect of postoperative recurrence.24–30
Four trials have evaluated the role of mesalamine versus
placebo and the effect on clinical recurrence.25,27–29 In the
overall analysis mesalamine was more effective than place-
bo in preventing clinical recurrence (mean difference 8.8%,
CI 95% 2.0–15.7%, P=0.012), Fig. 2a.
Endoscopic recurrence was evaluated in five trials
comparing mesalamine with placebo.24–28 Meta-analysis of
those studies did not show overall difference in postopera-
tive endoscopic recurrence (mean difference 13.5%, CI 95%
−6.0–33%, P=0.175), Fig. 2b.
Caprilli et al. compared two different dose regimens of
mesalamine, 2.4 g vs 4 g per day. This study did not show a
clinically significant difference in the prevention of postop-
erative endoscopic or clinical recurrence.30
Surgical recurrence was not evaluated in controlled trials.3.2.2. Metronidazole/ornidazole
Nitroimidazolic antibiotics have been shown to be effective
in preventing clinical and endoscopic postoperative recur-
rence of CD. Rutgeerts et al. published a trial comparing
metronidazole vs. placebo (for 3 months) as well as ornidazole
vs. placebo (for 12 months).31,32 Metronidazole showed onlyBlinding Incomplete outcome
data addressed
Free of selective
reporting
Yes Yes Yes
No Yes Yes
Yes Yes Yes
Yes Yes Yes
Yes Yes Yes
Yes Yes Unclear
Yes Yes Yes
Yes Yes Yes
Yes Yes Yes
Yes Yes Yes
No Yes Yes
Yes Yes Yes
Yes Yes Yes
Yes Yes Yes
Yes Yes Yes
Yes No Yes
Yes Yes Yes
Yes Yes Yes
Yes Yes Yes
Yes Yes Yes
Yes Yes Yes
Unclear Yes Yes
Yes Yes Yes
Yes Yes Yes
No Yes Yes
Table 2 Overview of effectiveness of different drug
therapies and surgical techniques on recurrence of CD.
Drug therapy/surgical
technique
Effectiveness
on recurrence
References
Mesalamine
Endoscopic No 24–28
Clinical Yes 25,27–29
Surgical Unclear
Nitroimadazolic antibiotics
Endoscopic Yes 31,32
Clinical Yes at 1 year;
no at 3 years
31,32;
31,32
Surgical Unclear
Thiopurines
Endoscopic Yes 28,34,35
Clinical No at 1 year;
yes at 2 years
28,33–35;
28,33
Surgical No 33
Budenoside
Endoscopic No 36,37
Clinical No 37
Surgical Unclear
Probiotics
Endoscopic No 39–41
Clinical No 39,40
Surgical Unclear
Interleukin-10
Endoscopic No 42
Clinical Unclear
Surgical Unclear
Infliximab
Endoscopic Yes 9
Clinical No 9
Surgical Unclear
Length of resection margin
Endoscopic Unclear
Clinical No 43
Surgical No 43
Type of anastomosis
Endoscopic No 44
Clinical No 44,46
Surgical
S–E vs E–E No 44
Stapled vs handsewn Yes at 7 years;
No
45; 46
Laparoscopic vs. open resection
Endoscopic No
Clinical Unclear 47
Surgical No 47
Figure 2 Overall analysis of controlled trials evaluating the
effect of mesalamine versus placebo on the prevention of
a. clinical recurrence (heterogeneity, P=0.752). b: endoscopic
recurrence (heterogeneity, Pb0.001).
641Prevention of postoperative recurrence of Crohn's diseaseborderline significant difference in reducing the postoperative
clinical recurrence compared to placebo at one year follow-
up. Overall analysis showed that nitroimidazolic antibiotics
are more effective than placebo in preventing postoperative
clinical recurrence at 1 year follow-up (mean difference
24.2%, CI 95% 11.6–36.9%, Pb0.001), Fig. 3a. However, at
3 year follow-up there was no significant difference anymore
(mean difference 9.3%, CI 95% −7.4–25.9%, P=0.276), Fig. 3b.
At 3 months follow-up endoscopic recurrence was signifi-
cantly reduced in an overall analysis (mean difference 23.7%,CI 95% 6.4–41.4%, P=0.007), Fig. 3c. At 1 year follow-up
data were only available from the ornidazole-trial. There
was still a significant difference in endoscopic recurrence
rate, with 53.6% in the ornidazole group, compared with
78.8% in the placebo group (P=0.037).
Surgical recurrence was not evaluated.
3.2.3. Thiopurines (azathioprine and 6-mercaptopurine)
The efficacy of thiopurine in preventing postoperative CD
is still not clear. Four controlled trials comparing azathio-
prine or 6-MP with placebo or mesalamine have been
published.28,33–35
Overall analysis showed no significant difference in pre-
venting postoperative clinical recurrence at one year
follow-up, comparing AZA/6-MP to placebo or mesalamine
(mean difference 3.8%, CI 95% −3.6–11.1%, P=0.316),
Fig. 4a. At two year follow-up only two studies were avail-
able, however, they showed that thiopurines are more ef-
fective than placebo or mesalamine in preventing clinical
recurrence (mean difference 13.1%, CI 95% 2.3–23.9%,
P=0.018), Fig. 4b.
Endoscopic recurrence rate at one year showed a signifi-
cant difference in favor of AZA/6-MP compared to placebo
(mean difference 19.7%, CI 95% 8.4–31.0%, P=0.001),
Fig. 4c. Hanauer showed that 6-MP was more effective
than placebo or mesalamine in preventing endoscopic recur-
rence at two years follow-up as well (difference 21.7%, CI
95% 4.3–39.2%, P=0.015).
Ardizzone showed that after 24 months of treatment
there was no significant difference in surgical recurrence
Figure 3 Overall analysis of controlled trials evaluating the
effect of metro-/ornidazole versus placebo on the prevention
of a. clinical recurrence at 1 year follow-up (heterogeneity,
P=0.373). b. clinical recurrence at 3 years follow-up (heteroge-
neity, P=0.309). c. endoscopic recurrence at 3 months follow-
up (heterogeneity, P=0.927).
Figure 4 Overall analysis of controlled trials evaluating the
effect of thiopurines versus placebo/mesalamine on the preven-
tion of a. clinical recurrence at 1 year follow-up (heterogeneity,
P=0.069). b. clinical recurrence at 2 years follow-up (heteroge-
neity, P=0.596). c. endoscopic recurrence at 1 year follow-up
(heterogeneity, P=0.750).
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rate of 6% vs. 10% respectively (P=0.5).3.2.4. Budenoside
Two controlled trials evaluated the effect of budenoside
on the prevention of postoperative recurrence of CD.36,37
Overall analysis did not show any difference in endoscopic
recurrence rate at one year follow-up (mean difference
7.9%, CI 95% −6.0–21.9%, P=0.263), Fig. 5.
Clinical recurrence, evaluated by Hellers et al., was not
different after one year follow-up between budenoside and
placebo (32% vs. 31% respectively).
Surgical recurrence was not evaluated.3.2.5. Probiotics
Chermesh et al. evaluated 30 patients receiving Synbiotic
2000, a mixture of prebiotics and probiotics, including 4 lac-
tic acid bacteria and 4 fermentable fibers, or placebo. They
did not find a significant difference in mean Rutgeerts score
at endoscopy at three and 24 months follow-up between
both groups.38Meta-analysis of three controlled trials did not show differ-
ence between probiotics and placebo on endoscopic recur-
rence (mean difference 1.5%, CI 95% −12.0–14.9%, P=0.831),
Fig. 6a.39–41 Two studies did not show statistical difference
on clinical recurrence as well (mean difference −3.6%, CI 95%
−13.5–6.4%, P=0.481), Fig. 6b.
Surgical recurrence was not evaluated.
3.2.6. Interleukin-10 (IL-10)
The importance of IL-10 for regulation of mucosal inflam-
mation has been investigated in several animal models of in-
flammatory bowel disease. Colombel et al. evaluated the
role of subcutaneously IL-10 in preventing postoperative en-
doscopic recurrence in humans. There was no difference in
endoscopic recurrence rates at 12 weeks follow-up (53% in
IL-10 group vs. 55% in placebo).42
Data about clinical and surgical recurrence were not
assessed.
3.2.7. Infliximab
A recent study by Regueiro et al. evaluated the role of
infliximab in preventing endoscopic and clinical recurrence
Figure 5 Overall analysis of controlled trials evaluating the
effect of budenoside versus placebo on the prevention of endo-
scopic recurrence at 1 year follow-up (heterogeneity, P=0.591).
643Prevention of postoperative recurrence of Crohn's diseasein a study with 24 patients.9 The endoscopic recurrence rate
at one year follow-up was significantly lower in the inflixi-
mab group compared to placebo (9.1% vs. 84.6%,
P=0.0006). The clinical recurrence rate at one year follow-
up was also lower in the infliximab group, although this did
not reach statistical significance (20.0% vs. 46.2%, P=0.38).
Surgical recurrence was not evaluated.
3.3. Surgical procedure
3.3.1. Length of resection margin
Fazio et al. reported about the role of resection margins
on postoperative recurrence in the small bowel.43 TheyFigure 6 Overall analysis of controlled trials evaluating the
effect of probiotics versus placebo on the prevention of a. endo-
scopic recurrence at 1 year follow-up (heterogeneity, P=0.169).
b. clinical recurrence at 1 year follow-up (heterogeneity,
P=0.798).evaluated a total of 131 patients, with a mean follow-up of
55.7 months. 75 patients underwent a limited resection
with a proximal margin of 2 cm of macroscopically non-
involved bowel, and 56 patients underwent an extended re-
section with a proximal margin of 12 cm of macroscopically
non-involved bowel. There was no difference in clinical re-
currence with 33% vs. 29% between the limited and extended
resections respectively, and also no statistical difference in
surgical recurrence with 25% and 18% respectively.
3.3.2. Type of anastomosis
The type of anastomosis following resection is one of the
important issues in the surgical management of Crohn's
disease.
Cameron et al. compared 35 patients with a side-to-end
anastomosis with 43 patients with an end-to-end anastomo-
sis after ileocolic resection.44 There was no difference in
clinical recurrence, 51% in both groups. Endoscopic recur-
rence was not evaluated in all patients. Surgical recurrence
was not statistically different as well, with six patients (17%)
in the side-to-end group who needed re-resection, compared
with three patients (7%) in the end-to-end group.
Ikeuchi et al. showed a significant lower rate of surgical re-
currence at the perianastomotic site after a stapled end-to-
end anastomosis compared to a double-layer handsewn anasto-
mosis after seven years of follow-up, 18% vs. 49% (P=0.022).45
A recent multicenter study by McLeod et al. analyzed
clinical and endoscopic recurrence rates in 139 patients
who underwent ileocolic resection.46 Stapled side-to-side
anastomosis was performed in 66 patients and handsewn
end-to-end anastomosis in 73 patients. There was no differ-
ence in clinical or endoscopic recurrence at one year follow-
up, with 23% and 38% in the stapled S–S group vs. 22% and
42% in the handsewn E–E group respectively.
Overall analysis comparing S–E or S–S with E–E anasto-
mosis did not show any statistical difference in clinical re-
currence (mean difference −0.7%, CI 95% −12.4–11.1%,
P=0.913), Fig. 7.
3.3.3. Laparoscopic vs. open resection
Laparoscopic ileocolic resection has been reported to have
short-term benefits compared to open resection, in terms of
reducing postoperative ileus and shorter length of hospital
stay. Recent studies by Stocchi et al. have evaluated the
long-term results with recurrence as endpoints.47 They evalu-
ated 56 patients, with a mean follow-up 10.5 years. 27 pa-
tients underwent laparoscopic ileocolic resection and 29
patients open ileocolic resection. There was no difference in
endoscopic recurrence with 48% after laparoscopic and 66%
after open resection.
Surgical recurrence of 26% and 28%, respectively, was
also not significant different between groups.
4. Discussion
In this combined systematic review with meta-analyses we
analyzed multiple drug regimens and surgical techniques in
preventing postoperative recurrence of CD.
The goals of treatment of CD should be to prevent postop-
erative recurrence that requires further medical or surgical
treatment, thus to prevent clinical or surgical recurrence.
Figure 7 Overall analysis of controlled trials evaluating the
effect of side–end anastomosis versus end–end anastomosis on
the prevention of clinical recurrence at 1 year follow-up
(heterogeneity, P=0.968).
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term follow-up. Endoscopy, however, can reveal new epitheli-
al lesions in the first year after surgery, and the severity of
these lesions predicts the recurrence of clinical symptoms.21
Although surgical recurrence is not as relevant for the short-
term follow-up, it definitely is at long-term follow-up.
Studies with mesalamine versus placebo have shown dif-
ferent results. Overall, mesalamine seems to be effective
in moderately preventing postoperative clinical recurrence
of CD. Endoscopic recurrence, however, is not prevented
by mesalamine.
Nitroimidazolic antibiotics (metronidazole or ornidazole)
appear to be effective in delaying the clinical recurrence,
as well as to prevent endoscopic recurrence at one year
follow-up. However, a high percentage of dropouts caused
by side-effects was observed. More trials with larger num-
bers of patients are needed before stating that these drugs
are really effective.
Meta-analyses of thiopurines showed significantly better
results in preventing postoperative recurrence of CD. Pa-
tients treated with thiopurines have a significantly lower
likelihood of postoperative clinical recurrence of CD at one
and two years follow-up compared with patients treated
with placebo or mesalamine. The endoscopic recurrence
rate is significantly lower as well with thiopurines than
with placebo or mesalamine. Surgical recurrence, analyzed
in one RCT, was not different after treatment with azathio-
prine compared to mesalamine. The study by Hanauer et al.
was criticized because the authors used a suboptimal dose of
6-MP, the high dropout rate, and the rate of clinical recur-
rence was higher than the endoscopic recurrence rate. How-
ever, this study had a weight of only 18% in the overall
analysis of the four studies included and the impact is there-
fore small. Interestingly, thiopurines were still effective for
the prevention of both clinical and endoscopic recurrence
when excluding mesalamine arms (data not shown).
Budenoside and probiotics are not effective and will not
prevent postoperative clinical and endoscopic recurrence
of CD, as shown in different RCTs.
There is also no evidence that interleukin-10 can prevent
endoscopic recurrence of CD. However, there is only one
RCT that investigated recurrence of CD at just 12 weeks
follow-up. Larger studies with longer follow-up are neededto get more insight in the role of interleukin-10 in preventing
of postoperative recurrence of CD.
In contrast, infliximab is effective in preventing endo-
scopic recurrence of CD. There is a higher proportion of
patients in clinical remission as well, although not statisti-
cally significant. More and larger studies are necessary to in-
vestigate the results of infliximab at long-term follow-up. In
this context, the PREVENT-study, an international, multi-
center trial, is being conducted. In this trial, patients who
underwent ileocolonic resection will be randomized to treat-
ment with infliximab or placebo every eight weeks through
week 200, with the goal to prevent recurrence of the disease
after surgical resection. The primary endpoints will be clini-
cal or endoscopic recurrence at 76 weeks.48
The length of the resection margin does not influence the
postoperative endoscopic and surgical recurrence rates of
CD. Therefore, ‘radical’ resections should be avoided and a
two centimeter margin of macroscopically normal bowel
seems adequate.
Different trials have evaluated different types of anasto-
mosis, but none of them seems to prevent postoperative clin-
ical and endoscopic recurrence of CD. In one trial surgical
recurrence was lower after a handsewn anastomosis than
after a stapled end-to-end anastomosis at long-term follow-
up. However, this trial used a very heterogeneous group of pa-
tients with different parts of bowel segments resected.
Although laparoscopic resection seems to have short-
term advantage, long-term follow-up did not show any ben-
efit in terms of postoperative clinical, endoscopic and surgi-
cal recurrence of CD. Nevertheless, especially in young
patients, laparoscopic resection has a cosmetic benefit.
Variations in the definitions of recurrence and in length of
follow-up in the different trials are limitations of this study.
Most studies have a follow-up period that is too short to be
adequate to show any difference in surgical recurrence
rates. Variations in inclusion and exclusion criteria regarding
disease phenotype (fistulising vs. stenosis) and type of bowel
resection may influence the results as well.
Although many drug regimens and surgical techniques
have been studied in RCTs, only thiopurines showed really
promising results in preventing postoperative clinical as
well as endoscopic recurrence of CD. Nitroimidazolic antibi-
otics are also effective in preventing clinical and endoscopic
recurrence at one year follow-up, however, in the long-term
follow-up there was no difference anymore in clinical recur-
rence rate. This might suggest that nitroimidazolic antibi-
otics are not able to prevent clinical recurrence, but only
delay recurrence of disease. Mesalamine decreases the clin-
ical recurrence rate and early endoscopic recurrence, how-
ever, does not affect the endoscopic recurrence rate after
one year follow-up. Infliximab seems promising in prevent-
ing endoscopic recurrence. As surgical recurrence needs a
longer follow-up to occur than clinical and endoscopic recur-
rence, the effect of all these regimens still remains unclear.
Therefore, large controlled trials with long-term follow-up
are needed to specifically study how different regiments
affect or prevent surgical recurrence of CD.
4.1. Practical guidelines
To our opinion, together with the results of randomized
clinical trials included in this meta-analysis the following
645Prevention of postoperative recurrence of Crohn's diseasepractical clinical guidelines can be made (Level of Evidence
[LoE] and Grade of Recommendation [GoR],49,50 Table 3).
• Mesalamine is effective in reducing the risk of postoperative
clinical recurrence.
• Maintenance therapy with thiopurines or nitroimidazolic antibi-
otics are both effective in reducing the risk of postoperative
clinical and endoscopic recurrence (LoE 1a, GoR A).
• Infliximab is effective to reduce the risk of postoperative endo-
scopic recurrence and seems promising in preventing postopera-
tive clinical recurrence, but larger studies are required (LoE 1b,
GoR A).
• For the straightforward ileocoecal resection for CD a two centi-
meter resection margin with an anastomosis of sufficient diame-
ter is required (either side-side or end-end) (LoE 1b, GoR A).
• The type of anastomosis does not influence the postoperative re-
currence rates (LoE 1a, GoR A).
• Laparoscopic surgery has the preference over open surgery, es-
pecially in young patients, because of the cosmetic benefits,
but it does not influence the postoperative recurrence rates
(LoE 2b, GoR B).
Because recurrence rates are high, postoperative prophy-
lactic treatment is justified. Overall, the clinician must out-
weigh the risk of each postoperative treatment against the
numbers needed to treat to prevent a single recurrence. So,
in patients with high-risk of postoperative recurrence a more
aggressive treatment is justified. Thiopurines are more effec-
tive than mesalamine in preventing postoperative clinical re-
currence, as well as endoscopic recurrence. However, they
are more harmful as well, and therefore should be given in pa-
tients with high-risk of recurrence only. In patients with low
risk of recurrencemesalamine should be sufficient or no treat-
ment at all, according to the CD Guidelines by the European
Crohn's and Colitis Organisation.51 The role of the promising
anti-TNF agents is still unclear (LoE 5, GoR D).
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